MicroRNA-mediated control of macrophages and its implications for cancer

Trends in Immunology

Volumn 34, Issue 7, 2013, Pages 350-359

  Squadrito, Mario Leonardo ^a   Etzrodt, Martin ^b,c   De Palma, Michele ^a   Pittet, Mikael J ^b  

^a EPFL   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

cancer; inflammation; miRNA; monocyte; tumor associated macrophage

Indexed keywords

CHEMOKINE RECEPTOR CCR2; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MICRORNA; MICRORNA 125B; MICRORNA 146; MICRORNA 146A; MICRORNA 155; MICRORNA 20B; MICRORNA 21; MICRORNA 223; MICRORNA 29B; MICRORNA 511; MICRORNA 9; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR PU 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GROWTH; CELL ACTIVATION; CELL COMMUNICATION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; GRANULOPOIESIS; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; MONONUCLEAR PHAGOCYTE; MYELOID PROGENITOR CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PERITONEUM MACROPHAGE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MICRORNAS; NEOPLASMS;

EID: 84880772300     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.02.003     Document Type: Review

References (100)

1. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
2. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
3. Lindsay M.A. microRNAs and the immune response. Trends Immunol. 2008, 29:343-351.
4. Mitra A.K., et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012, 2:1100-1108.
5. O'Connell R.M., et al. microRNA regulation of inflammatory responses. Annu. Rev. Immunol. 2012, 30:295-312.
6. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
7. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
8. Ruffell B., et al. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012, 33:119-126.
9. Squadrito M.L., De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Aspects Med. 2011, 32:123-145.
10. Cortez-Retamozo V., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2491-2496.
11. Ugel S., et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012, 2:628-639.
12. Sawanobori Y., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
13. Cortez-Retamozo V., et al. Regulation of macrophage and dendritic cell responses by their lineage precursors. J. Innate Immun. 2012, 4:411-423.
14. Guo S., et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14229-14234.
15. Lechman E.R., et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 2012, 11:799-811.
16. Ghani S., et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood 2011, 118:2275-2284.
17. Jurkin J., et al. miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J. Immunol. 2010, 184:4955-4965.
18. Velu C.S., et al. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009, 113:4720-4728.
19. Fazi F., et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007, 12:457-466.
20. Starnes L.M., et al. NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood 2009, 114:1753-1763.
21. Schuler A., et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood 2008, 111:4532-4541.
22. Fontana L., et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat. Cell Biol. 2007, 9:775-787.
23. Pospisil V., et al. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J. 2011, 30:4450-4464.
24. Rosa A., et al. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19849-19854.
25. Nahrendorf M., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007, 204:3037-3047.
26. Etzrodt M., et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 2012, 1:317-324.
27. Zhao J.L., et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9184-9189.
28. Cortez-Retamozo V., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:296-308.
29. Jazdzewski K., et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1502-1505.
30. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
31. Mantovani A., et al. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013, 229:176-185.
32. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
33. Kulshreshtha R., et al. A microRNA signature of hypoxia. Mol. Cell. Biol. 2007, 27:1859-1867.
34. O'Connell R.M., et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1604-1609.
35. Bala S., et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J. Biol. Chem. 2011, 286:1436-1444.
36. Tili E., et al. miR-155: on the crosstalk between inflammation and cancer. Int. Rev. Immunol. 2009, 28:264-284.
37. Androulidaki A., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231.
38. Wang P., et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 2010, 185:6226-6233.
39. Nazari-Jahantigh M., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 2012, 122:4190-4202.
40. Martinez-Nunez R.T., et al. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J. Biol. Chem. 2011, 286:1786-1794.
41. Cai X., et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J. Mol. Cell Biol. 2012, 4:341-343.
42. He M., et al. MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. Cell. Mol. Immunol. 2009, 6:343-352.
43. Huffaker T.B., et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2012, 2:1697-1709.
44. Ceppi M., et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2735-2740.
45. Tang B., et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 2010, 584:1481-1486.
46. Zhou H., et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010, 116:5885-5894.
47. O'Connell R.M., et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7113-7118.
48. Graff J.W., et al. Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 2012, 287:21816-21825.
49. Tili E., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
50. Kim S.W., et al. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7865-7870.
51. Chaudhuri A.A., et al. MicroRNA-125b potentiates macrophage activation. J. Immunol. 2011, 187:5062-5068.
52. Taganov K.D., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12481-12486.
53. Boldin M.P., et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 2011, 208:1189-1201.
54. Bazzoni F., et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:5282-5287.
55. Sheedy F.J., et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2010, 11:141-147.
56. Liu G., et al. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15819-15824.
57. Saccani A., et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
58. Asangani I.A., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
59. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
60. Zhuang G., et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 2012, 125:2892-2903.
61. Rossato M., et al. IL-10-induced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E3101-E3110.
62. Ruckerl D., et al. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 2012, 120:2307-2316.
63. Squadrito M.L., et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep. 2012, 1:141-154.
64. Martinez-Pomares L. The mannose receptor. J. Leukoc. Biol. 2012, 92:1177-1186.
65. Tserel L., et al. MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J. Biol. Chem. 2011, 286:26487-26495.
66. Chang H.T., et al. Comprehensive analysis of microRNAs in breast cancer. BMC Genomics 2012, 13:S18.
67. Montecalvo A., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
68. Yang M., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10:117.
69. Fabbri M., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2110-E2116.
70. Pucci F., Pittet M.J. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin. Cancer Res 2013, 10.1158/1078-0432.CCR-12-0962.
71. Kumar M.S., et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
72. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 2009, 10:578-585.
73. Cubillos-Ruiz J.R., et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012, 72:1683-1693.
74. Bader A.G., et al. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
75. Elmen J., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
76. Lanford R.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
77. Baek D., et al. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
78. Guo H., et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
79. Miska E.A., et al. Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet. 2007, 3:e215.
80. Park C.Y., et al. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 2012, 1:385-391.
81. Mullokandov G., et al. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods 2012, 9:840-846.
82. Grimson A., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
83. Pasquinelli A.E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 2012, 13:271-282.
84. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
85. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
86. Calin G.A., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
87. Ryan B.M., et al. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10:389-402.
88. Mantovani A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
89. Arranz A., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9517-9522.
90. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011, 11:750-761.
91. Martinez F.O., et al. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
92. Biswas S.K., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
93. Pucci F., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
94. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 2002, 277:32124-32132.
95. Hagemann T., et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
96. DeNardo D.G., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
97. He H., et al. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood 2012, 120:3152-3162.
98. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
99. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
100. Movahedi K., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.